BofA lowered the firm’s price target on Bath & Body Works to $40 from $45 and keeps a Buy rating on the shares. After the Q1 earnings report, the firm is lowering its FY25 and FY26 EPS estimates by 3% and 4%, respectively, to reflect tariff pressure and a more cautious fiscal year outlook, but adds that it thinks Bath & Body’s accelerating sales growth and strong margin profile deserves a higher multiple.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Positive Outlook for Bath & Body Works Driven by Strategic Leadership and Innovation
- Buy Rating for Bath & Body Works: Promising Sales Growth and Strategic Innovation Amid Tariff Challenges
- Bath & Body Works price target lowered to $30 from $35 at Barclays
- Bath & Body Works Reports Strong Q1 2025 Results
- Bath & Body Works Reports Strong Q1 Earnings